TB Research

Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives

Alsayed SSR, Lun S, Payne A, Bishai WR, Gunosewoyo H

Chemical biology & drug design · 2021-03

Abstract

Several rationally designed isoniazid (INH), pyrazinamide (PZA) and ciprofloxacin (CPF) derivatives were conveniently synthesized and evaluated in vitro against H37Rv Mycobacterium tuberculosis (M. tb) strain. CPF derivative 16 displayed a modest activity (MIC = 16 µg/ml) and was docked into the M. tb DNA gyrase. Isoniazid-pyrazinoic acid (INH-POA) hybrid 21a showed the highest potency in our study (MIC = 2 µg/ml). It also retained its high activity against the other tested M. tb drug-sensitive strain (DS) V4207 (MIC = 4 µg/ml) and demonstrated negligible cytotoxicity against Vero cells (IC 50 ≥ 64 µg/ml). Four tested drug-resistant (DR) M. tb strains were refractory to 21a, similar to INH, whilst being sensitive to CPF. Compound 21a was also inactive against two non-tuberculous mycobacterial (NTM) strains, suggesting its selective activity against M. tb. The noteworthy activity of 21a against DS strains and its low cytotoxicity highlight its potential to treat DS M. tb.

MeSH terms

  • Vero Cells
  • Animals
  • Mycobacterium tuberculosis
  • Isoniazid
  • Pyrazinamide
  • Ciprofloxacin
  • DNA Gyrase
  • Antitubercular Agents
  • Microbial Sensitivity Tests
  • Drug Resistance, Bacterial
  • Cell Survival
  • Binding Sites
  • Catalytic Domain
  • Molecular Conformation
  • Structure-Activity Relationship
  • Drug Design
  • Nontuberculous Mycobacteria
  • Molecular Docking Simulation
  • Chlorocebus aethiops